ICOS and experimental autoimmune encephalomyelitis: Models of autoimmunity revealed that ICOS signaling is critical for T cell-mediated pathogenicity in experimental autoimmune encephalomyelitis and the development of type 1 diabetes [8], and that ICOS blockade could be efficacious in treating on-going activated T cell responses and reversing autoimmunity during active disease [9, 10].